Description

Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.–80°C, protect from light-Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Keiji Furuuchi, et al. Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models. Cancer Sci. 2021 Jun;112(6):2467-2480.|[2]Xin Cheng, et al. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675.-CASNumber-2407465-18-1-MolecularWeight-149000 (average)-Compound Purity-97.87-SMILES-[Farletuzumab ecteribulin]-Research_Area-Cancer-Solubility-H2O-Target-Antibody-Drug Conjugates (ADCs)-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related